8-K: Verrica Pharmaceuticals Faces Nasdaq Delisting Warning Due to Low Stock Price

Verrica Pharmaceuticals received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Summary

• Verrica Pharmaceuticals received a notice from Nasdaq on January 24, 2025, stating that its common stock is not in compliance with Nasdaq Listing Rule 5450(a)(1).
• The non-compliance is due to the company's stock price being below $1.00 per share for the previous 30 consecutive business days.
• Verrica has a 180-day period, until July 23, 2025, to regain compliance by having its stock price close at $1.00 or more for at least 10 consecutive business days.
• If the company fails to regain compliance within this period, it may be eligible for additional time by transferring to the Nasdaq Capital Market, which requires submitting a transfer application and a $5,000 fee.
• To qualify for the Nasdaq Capital Market, Verrica must meet continued listing requirements for market value of publicly held shares and all other initial listing standards, except the minimum bid price.
• The company may also need to effect a reverse stock split to cure the deficiency.
• If Verrica fails to regain compliance, Nasdaq will provide notice that the company's shares will be subject to delisting, which the company may appeal.
• Verrica intends to monitor its stock price and consider available options to regain compliance, including transferring to the Nasdaq Capital Market or effecting a reverse stock split.
• There is no assurance that the company will be successful in maintaining its listing on the Nasdaq Global Market or the Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: The news is negative as it indicates financial distress and potential delisting, but the company has options to regain compliance.

Positives

• The notice has no present impact on the listing of the company's securities on the Nasdaq Global Market.
• Verrica has options to regain compliance, including a 180-day grace period and the possibility of transferring to the Nasdaq Capital Market.

Negatives

• Verrica's stock price has fallen below the minimum bid price required for continued listing on the Nasdaq Global Market.
• There is no guarantee that Verrica will be able to regain compliance and avoid delisting.

Risks

• Failure to regain compliance with Nasdaq listing rules could result in the delisting of Verrica's common stock.
• The company may need to undertake a reverse stock split, which could negatively impact shareholder value.
• There is a risk that Nasdaq staff may not believe the company will be able to cure the deficiency, leading to a delisting notice.

Future Outlook

Verrica intends to actively monitor its minimum bid price and consider available options to resolve the deficiencies and regain compliance with the Nasdaq Listing Rules, including applying to transfer to the Nasdaq Capital Market or effecting a reverse stock split.

Industry Context

Many small-cap pharmaceutical companies face challenges in maintaining Nasdaq listing compliance due to stock price volatility and the inherent risks associated with drug development and regulatory approvals. Delisting can significantly impact investor confidence and access to capital.

Comparison to Industry Standards

• Other small-cap biotech companies facing similar listing challenges often consider reverse stock splits to artificially inflate their stock price and meet Nasdaq's minimum bid requirement.
• Companies like Agenus Inc. and Diffusion Pharmaceuticals Inc. have previously implemented reverse stock splits to maintain their Nasdaq listings.
• The success of these strategies varies, and depends on the company's underlying financial performance and future prospects.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation worsens.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• Verrica will monitor its stock price.
• Verrica will consider available options to resolve the deficiencies and regain compliance with the Nasdaq Listing Rules.
• Verrica may apply to transfer to the Nasdaq Capital Market.
• Verrica may effect a reverse stock split.

Key Dates